Literature DB >> 18984663

Copeptin in the differential diagnosis of hyponatremia.

Wiebke Fenske1, Stefan Störk, Anne Blechschmidt, Sebastian G K Maier, Nils G Morgenthaler, Bruno Allolio.   

Abstract

BACKGROUND: Treatment of patients with hyponatremia varies widely; thus, convenient diagnostic parameters are needed to guide the correct treatment strategy. This study was designed to evaluate the diagnostic potential of copeptin, the C-terminal part of provasopressin, as a new marker in the differential diagnosis of hyponatremia.
METHODS: In this prospective observational study, 106 consecutive hyponatremic patients were classified based on their history, clinical evaluation, and laboratory tests. In patients and 32 healthy control subjects, plasma copeptin concentration and standard biochemical parameters were tested for their utility of diagnosing the syndrome of inappropriate antidiuresis (SIAD).
RESULTS: Four patients (4%) were diagnosed as primary polydipsia, nine (8%) as diuretic-induced hyponatremia, 42 (40%) as SIAD, 29 (27%) as hypovolemic hyponatremia, and 22 patients (21%) as hypervolemic hyponatremia. In controls, a close correlation between plasma copeptin and serum sodium (r(2) = 0.62, P < 0.001) or urine osmolality (r(2) = 0.39, P = 0.001) was observed. Plasma copeptin levels were significantly higher in patients with hypo- and hypervolemic hyponatremia compared with SIAD (P < 0.005, respectively) and primary polydipsia (P < 0.001). The copeptin to U-Na ratio differentiated accurately between volume-depleted and normovolemic disorders (area under the receiver-operating characteristic curve 0.88, 95% confidence interval 0.81-0.95; P < 0.001), resulting in a sensitivity and specificity of 85 and 87% if a cutoff value of 30 pmol/mmol was used. The combined information of plasma copeptin less than 3 pmol/liter and urine osmolality less than 200 mOsm/kg ensured primary polydipsia in 100% of suspected patients.
CONCLUSION: Copeptin measurement reliably identifies patients with primary polydipsia but has limited utility in the differential diagnosis of other hyponatremic disorders. In contrast, the copeptin to U-Na ratio is superior to the reference standard in discriminating volume-depleted from normovolemic hyponatremic disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18984663     DOI: 10.1210/jc.2008-1426

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  48 in total

1.  Changes in copeptin and bioactive vasopressin in runners with and without hyponatremia.

Authors:  Tamara Hew-Butler; Martin D Hoffman; Kristin J Stuempfle; Ian R Rogers; Nils G Morgenthaler; Joseph G Verbalis
Journal:  Clin J Sport Med       Date:  2011-05       Impact factor: 3.638

Review 2.  Hyponatraemia - presentations and management.

Authors:  Rosemary Dineen; Christopher J Thompson; Mark Sherlock
Journal:  Clin Med (Lond)       Date:  2017-06       Impact factor: 2.659

3.  Plasma copeptin and the risk of diabetes mellitus.

Authors:  Sofia Enhörning; Thomas J Wang; Peter M Nilsson; Peter Almgren; Bo Hedblad; Göran Berglund; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Eero Lindholm; Leif Groop; Valeria Lyssenko; Marju Orho-Melander; Christopher Newton-Cheh; Olle Melander
Journal:  Circulation       Date:  2010-05-03       Impact factor: 29.690

Review 4.  Hyponatraemia: more than just a marker of disease severity?

Authors:  Robert W Schrier; Shailendra Sharma; Dmitry Shchekochikhin
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

5.  Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33).

Authors:  W E Boertien; I J Riphagen; I Drion; A Alkhalaf; S J L Bakker; K H Groenier; J Struck; P E de Jong; H J G Bilo; N Kleefstra; R T Gansevoort
Journal:  Diabetologia       Date:  2013-04-28       Impact factor: 10.122

Review 6.  [Hyponatremia in emergency admissions - often dangerous].

Authors:  W Fenske
Journal:  Internist (Berl)       Date:  2017-10       Impact factor: 0.743

7.  Current and future treatment options in SIADH.

Authors:  Robert Zietse; Nils van der Lubbe; Ewout J Hoorn
Journal:  NDT Plus       Date:  2009-11

8.  Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage.

Authors:  Christian Zweifel; Mira Katan; Philipp Schuetz; Martin Siegemund; Nils G Morgenthaler; Adrian Merlo; Beat Mueller; Mirjam Christ-Crain
Journal:  BMC Neurol       Date:  2010-05-26       Impact factor: 2.474

9.  Copeptin as a marker for arginine-vasopressin/antidiuretic hormone secretion in the diagnosis of paraneoplastic syndrome of inappropriate ADH secretion.

Authors:  A Wuttke; K C Dixit; G Szinnai; S C Werth; U Haagen; M Christ-Crain; N Morgenthaler; G Brabant
Journal:  Endocrine       Date:  2013-03-12       Impact factor: 3.633

Review 10.  SIAD: practical recommendations for diagnosis and management.

Authors:  M Cuesta; A Garrahy; C J Thompson
Journal:  J Endocrinol Invest       Date:  2016-04-19       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.